Information  X 
Enter a valid email address

Genus (GNS)

  Print          Annual reports

Tuesday 22 June, 2021


Capital Markets Event & PRRSv Programme Update

RNS Number : 6179C
Genus PLC
22 June 2021

For Immediate Release

22 June 2021

Genus plc

('Genus', the 'Company' or the 'Group')


Capital Markets Event and PRRSv Resistance Programme Update


Genus (LSE:GNS), a leading global animal genetics company, is hosting a Capital Markets Event ('CME') today at 3pm UK time. The CME will cover key strategic progress and initiatives being implemented to further strengthen Genus's leadership in the animal genetics market. The presentations given by members of Genus's executive management will be made available on the Company website after the event at  

As part of the CME, Genus's Chief Scientific Officer Dr. Elena Rice will provide an update on Genus's porcine reproductive and respiratory syndrome virus ('PRRSv') resistance programme, including the results of the most recent disease challenge for Genus's gene edited pigs. In the most recent trial, 40 animals (23 gene edited for PRRS resistance and 17 unedited animals), which were infected with two prevalent types of the PRRS virus, were tested. The trial demonstrated that the gene edited pigs were 100% resistant to both types of the PRRS virus, and confirms previous academic findings. In the next phase of the disease trials, Genus will be evaluating whether PRRSv resistance is preserved across generations by breeding and testing the offspring of the first generation of edited pigs. These trials will be included as part of the submissions to the US Food and Drug Administration as part of the regulatory review process. 

Any institutional in vestors and sell side analysts not already registered and wishing to attend the event should contact Buchanan at [email protected].


For further information please contact:

Genus plc

Tel: 01256 345970

Stephen Wilson, Chief Executive

Alison Henriksen, Group Finance Director



Tel: 0207 466 5000



Charles Ryland /Chris Lane


This announcement is available on the Genus website

About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t